Skip to Content

Hematologic Cancer Trials

A041702: A Randomized Phase III Study of Iburtinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (>70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) 
Aims: The purpose of this study is to discover if adding the drug Venetoclax will be better, the same or worse than the standard treatment and if stopping after 1 year of treatment is possible for those who have no detectable CLL.
Diagnosis: Chronic Lymphocytic Leukemia (CLL)
Principal investigator: David Grinblatt, MD
IRB Approval Number: EH19-149
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

EA9161: A Randomized Phase III Study of  the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib plus  Obinutuzumab in Untreated Younger  Patients with Chronic Lymphocytic Leukemia (CLL) 
Aims: The purpose of this study is to discover if adding the drug Venetoclax will be better, the same or worse than the standard treatment
Diagnosis: Chronic Lymphocytic Leukemia (CLL)
Principal investigator: David Grinblatt, MD
IRB Approval Number: EH19-150
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

A041501: A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody to Frontline Therapy in Young Adults (ages 18-39 years) with Newly Diagnosed Precursor B-Cell ALL.
Aims: The purpose of this study is to test the addition of an investigational drug, inotuzumab in addition to standard treatment for ALL.
Diagnosis: Acute Lymphocytic Leukemia (ALL)
Principal investigator: Lynne Kaminer, MD
IRB Approval Number: EH18-377
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570-1768
Open to Enrollment: Yes

A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
Aims: The purpose of this study is to discover the best combination and duration of treatment for patients with myeloma using drugs that have been recently approved for myeloma.
Diagnosis: Myeloma
Principal investigator: David Grinblatt, MD
IRB Approval Number: EH17-069
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

Celgene Connect MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Aims: There are three main purposes of this study: 1. To use the information collected to help better understand patterns for diagnosis, treatment, and outcomes, including disease progression and survival. 2. To use the information to help better understand patterns for the quality of life in patients newly diagnosed with Lower-Risk, Higher-Risk, or unknown risk MDS or AML. 3. To use the results of this study to provide information to help better understand the effect different treatments have on a patient’s disease and on their quality of life.
Diagnosis: Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH13-390
Sponsor: Celgene
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Aims: The purpose of this study is to compare the effects, good and/or bad, the therapy blinatumomab has on your type of cancer (BCR/ABL negative ALL). This investigational drug will be added to what has traditionally been used to treat your specific sub-type of ALL. Studies are being done in ALL and other blood cancers with blinatumomab. It is hoped that blinatumomab will target your B-cell ALL and destroy these specific cells, but it has not yet been proven.
Diagnosis: BRCA/ABL negative Acute Lymphoblastic Leukemia (ALL)
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH15-299
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

UTX-TGR-205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of Combination of Ublituximab + TGR-1202 with our without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Aims: The purpose of this study is to see how effective the combination of investigational drugs, ublituximab and umbraslisib are when given together compared to when umbralisib is given alone.
Diagnosis: Non-Hodgkin's lymphoma
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH17-290
Sponsor: TG Therapeutics
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CIBMTR: Protocol for Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries 
Aims: The purpose of this study is to collect information on the collection of peripheral blood stem cells, transplant of stem cells, and the outcomes of patients who undergo peripheral blood stem cell transplant
Diagnosis: For patients undergoing a peripheral blood stem cell transplant
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH15-249
Sponsor: National Marrow Donor Program
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

UC14-0899: Phase II Randomized Trial of Continuation of Post-Transplant Maintenance with Single-Agent Lenalidomide vs. Consolidation /Maintenance with Izaxomib-Lenalidomide-Dexamethasone in Patients with Residual Myeloma
Aims: The purpose of this study is to collect information on the combination of three treatments (Izaxomib-Lenalidomide and Dexamethasone)on the collection of peripheral blood stem cells, transplant of stem cells, and the outcomes of patients who undergo peripheral blood stem cell transplant
Diagnosis: For patients undergoing a peripheral blood stem cell transplant
Principal Investigator: David Grinblatt, MD 
IRB Approval Number: EH16-051
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

UC13-1406: Prospective, Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-associated B-Cell Lymphoma
Aims: The purpose of this study is to see the effects of the about the combination of 6 drugs - lenalidomide, etoposide, vincristine, rituxumab, cyclophosphamide and doxorubicin on lymphoma.
Diagnosis: B-Cell Lymphona
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH16-047
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768 
Open to Enrollment: Yes

UC16-1138: Open-label, Single-arm, Phase 2 Study of Initial Treatment with Elotuzumab, Carfilzomib, (Kyprolis), Lenalidomide (Revlimid) and Low dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
Aims: The purpose of this study is to see the effects of the combination of 4 drugs - lenalidomide, carfilzomib, elotuzumab and dexamethasone on myeloma.
Diagnosis: Multiple Myeloma
Principal Investigator: David Grinblatt, MD 
IRB Approval Number: EH18-075
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768 
Open to Enrollment: Yes

Astex SGI-110-07: A Phase 3, Multicenter, Randomized, Open-label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated Hypomethylating Agents
Aims: The purpose of this study is to see if AG-221 is safe and effective in treating AML compared to commonly used treatment options.
Diagnosis: Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia"
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH17-102
Sponsor: Astex
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes